Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Rande Is . . . HOME -- Ignore unavailable to you. Want to Upgrade?

To: Mark Konrad who wrote (20228)	2/10/2000 9:39:00 AM
From: Steven Finkel	Read Replies (2) \| Respond to of 57584

IMNR latest biotech to soar. Could be a great day trade. This news out this morning: The Immune Response Corporation Receives Two U.S. Patents On Immunotherapeutics for Prevention and Treatment of Retroviral Disease CARLSBAD, Calif., Feb. 10 /PRNewswire/ -- The Immune Response Corporation (Nasdaq: IMNR) announced today that it has received two patents from the United States Patent and Trademark Office covering methods and compositions relating to immune-based therapies for the prevention and treatment of retroviral diseases, such as Acquired Immune Deficiency Syndrome (AIDS). The claims in U.S. Patent Number 6,017,543 entitled "Prevention and Treatment of Retroviral Disease," which issued on January 25, 2000, cover the Company's methods of stimulating the immune system with whole, inactivated human immunodeficiency virus (HIV) in individuals who are either infected or not infected with HIV. An earlier issued patent, Number 5,895,650, of the same title, includes claims to whole, inactivated retroviral particles known to cause human diseases (viruses such as HTLV-1, HTLV-2, HIV-1 and HIV-2) in a physiologically acceptable solution. Retroviruses are viruses containing RNA as their genetic material, many of which cause disease. HIV is a retrovirus that causes AIDS. "Together, these patents grant the Company broad claims to immune-based therapies that use any whole, inactivated retrovirus, including HIV, in a solution compatible for use in humans in order to prevent or treat retroviral diseases," said Dennis J. Carlo, Ph.D., President and CEO. "We believe that the scope of these patents places the Company in a strong intellectual property position in the field of retroviral vaccine research. This is a position we vigorously intend to protect." The Company has previously been issued 5 other patents related specifically to the use of REMUNE(TM) or certain combinations of HIV-specific proteins, other than outer envelope proteins, as immune-based therapies. REMUNE is an immune-based therapy composed of whole HIV particles that have been depleted of their gp120 viral coat proteins and inactivated to render them non-infectious. The final formulation is emulsified in Incomplete Freund's Adjuvant, which is a potent immune stimulant acceptable for use in humans. REMUNE can be used alone or in combination with existing antiviral drug therapies for HIV and is intended to treat HIV-infected individuals by preventing or delaying the progression of HIV to AIDS. REMUNE is the subject of investigation in several clinical trials including a pivotal registration trial launched in September 1999 with Agouron Pharmaceuticals, Inc., the Company's partner for development and commercialization of REMUNE in the U.S., Europe, Australia, Japan and certain other countries. The Immune Response Corporation is a biopharmaceutical company based in Carlsbad, California, developing immune-based therapies to induce specific T-cell responses for the treatment of HIV and autoimmune diseases. In addition, the Company is working on cancer vaccines and gene therapy. NOTE: News releases are available through PR Newswire Company News On-Call fax service. For a menu of available news releases or to retrieve a specific release made by The Immune Response Corporation, please call 800-758-5804, extension 434675. Please retain this number for future reference. Company information can also be located on the Internet Web Site: imnr.com. This news release contains forward-looking statements. Actual results could vary materially from those expected due to a variety of risk factors, including, but not limited to, whether our patents will provide us with any meaningful protection, whether additional patents will be issued, whether clinical trials will be successfully concluded and whether REMUNE will be approved for marketing or be successfully commercialized. Those factors are discussed more thoroughly in The Immune Response Corporation's SEC filings, including but not limited to its report on Form 10-K for the year ended December 31, 1998 and subsequent Forms 10-Q. The Company undertakes no obligation to publicly release the result of any revisions to these forward-looking statements which may be made to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. REMUNE(TM) is a trademark of The Immune Response Corporation. --------------------------------------------------------------------------------

To: Mark Konrad who wrote (20228)	2/10/2000 1:41:00 PM
From: Rande Is	Read Replies (2) \| Respond to of 57584

Out of ISSX +9 on average. . .Out of WGRD + 7 1/2 on average. . .Out AXNT + 1 on average . . . hackers let me down <smirk>. . . One more thing. . I've gotta say. . . .you guys are doing a great job selling peaks and buying dips on LPTHA. . .you are keeping it far more liquid than it was around 20. . .or especially that first time it went into the 30's and was knocked down just as fast. . . the moves are now slow and steady. . .dips are quickly bought up and peaks are rounded off. . . . if MMs refuse to provide liquidity. . . we will handle it ourselves!! It has been trading in a predictable pattern and staying well within its trading range, while making slow gains and furthering its consolidation in the mid-30's, which was our goal. Great job. Rande Is